[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_101":102,"_103":57},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":16,"_18":-5,"_19":-5,"_20":21,"_22":23,"_24":25,"_26":27,"_28":25,"_29":30,"_31":32,"_33":34,"_35":36,"_37":38,"_39":-5,"_38":40,"_41":-5,"_42":-5,"_43":-5,"_44":45,"_46":47,"_48":-5,"_49":50,"_51":52,"_53":54,"_55":36,"_56":57,"_58":-5,"_59":60,"_61":62,"_63":36,"_64":36,"_65":66},"id","wxnxobir2jj8wd5shpajzjmk1","revision",2,"title","#AACR26","originalTitle","summary","reason","source",{"_11":95,"_77":96,"_97":98,"_99":36,"_100":-5},"links",{"_92":93,"_66":94},"publishedAt","2026-04-18T00:59:08.000Z","discoveredAt","2026-10-22T11:08:37.379Z","timelineAt","category","opinion","tags",[],"score",60,"selected",false,"channel","x","story",{"_85":86,"_87":47,"_88":-5,"_89":-5,"_90":91},"insight","digest","conferenceAbstracts","readingMode","full","author","DrMirallas","language","body",{"_81":-5,"_66":82,"_83":-5,"_84":57},"outline",[],"relatedStories",[],"indexable","markdownAvailable",true,"group","conference",{"_75":76,"_77":78,"_79":-5,"_80":-5},"engagement",{"_67":68,"_69":70,"_71":72,"_73":74},"posterIsAuthor","hasTranslation","bodyLanguage","original","heat",12,"likes",8,"replies",0,"reposts",4,"slug","aacr-2026","name","AACR 2026 年会","topic","reading","zh","

#AACR26

Exploiting #YAP #TEAD to overcome resistance to #target

@SilvioGutkind

@UCSDCancerCTO

LXS-196: Darovasertib #PKC #PKN +DATA in #uveal melanoma
#VT3989 increased efficacy in #mice
RAF-MEKi + FAKi #melanoma
#HNSCC PS1 and #VT3989

@OncoAlert

","zhKind","complete","authorName","Oriol Mirallas MD","handle","avatarUrl","quoted","media",[],"aihot","/items/wxnxobir2jj8wd5shpajzjmk1","https://x.com/DrMirallas/status/2045306097758777704","aacr26-floor","AACR 2026 现场信号","kind","x_search","firstParty","iconUrl","changelogVersion","2026-10-23T01:25","enEditionEnabled"]